Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Phase 3 Completed 688 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Compare the objective remission rate of A140 and Erbitux combined with mfolfox6 regimen in the first-line treatment of Ras wild-type metastatic colorectal cancer for 12 weeks

Timeline

Start: 2020-12-31
Primary completion: 2023-03-22
Completion: 2024-01-26

Publications

Liu R, Yin X, Bai Y, Zhong H, Ye F, Wang Q, Liu M, Li N, Deng Y, Wang Y, Xu J, Li W, Chen K, Cai S, Yang J, Zhang T, Li Y, Qin B, Deng L, Liu S, Li S, Si J, Li Y, Ge J, Xu N, Xu J. A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial. Eur J Cancer. 2025 Aug 26;226:115566. doi: 10.1016/j.ejca.2025.115566. Epub 2025 Jun 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	A140	Unknown	250 mg/m2	Intravenous
Subject	Cetuximab	Monoclonal antibody	250 mg/m2	Intravenous
Background	Leucovorin	Small molecule	400 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	fluorouracil	Small molecule	2400 mg/m2	Intravenous

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Summary

Timeline

Publications

Drugs

Indications